Matrix metalloproteinases: Expression, regulation and role in the immunopathology of tuberculosis
- PMID: 31199047
- PMCID: PMC6668971
- DOI: 10.1111/cpr.12649
Matrix metalloproteinases: Expression, regulation and role in the immunopathology of tuberculosis
Abstract
Mycobacterium tuberculosis (Mtb) leads to approximately 1.5 million human deaths every year. In pulmonary tuberculosis (TB), Mtb must drive host tissue destruction to cause pulmonary cavitation and dissemination in the tissues. Matrix metalloproteinases (MMPs) are endopeptidases capable of degrading all components of pulmonary extracellular matrix (ECM). It is well established that Mtb infection leads to upregulation of MMPs and also causes disturbance in the balance between MMPs and tissue inhibitors of metalloproteinases (TIMPs), thus altering the extracellular matrix deposition. In TB, secretion of MMPs is mainly regulated by NF-κB, p38 and MAPK signalling pathways. In addition, recent studies have demonstrated the immunomodulatory roles of MMPs in Mtb pathogenesis. Researchers have proposed a new regimen of improved TB treatment by inhibition of MMP activity to hinder matrix destruction and to minimize the TB-associated morbidity and mortality. The proposed regimen involves adjunctive use of MMP inhibitors such as doxycycline, marimastat and other related drugs along with front-line anti-TB drugs to reduce granuloma formation and bacterial load. These findings implicate the possible addition of economical and well-tolerated MMP inhibitors to current multidrug regimens as an attractive mean to increase the drug potency. Here, we will summarize the recent advancements regarding expression of MMPs in TB, their immunomodulatory role, as well as their potential as therapeutic targets to control the deadly disease.
Keywords: Mtb; Host-directed therapy; Immunopathology; MMPs; Signalling pathways.
© 2019 The Authors. Cell Proliferation Published by John Wiley & Sons Ltd.
Conflict of interest statement
All authors declare no conflict of interest.
Figures



Similar articles
-
Breaking the Cycle: Matrix Metalloproteinase Inhibitors as an Alternative Approach in Managing Tuberculosis Pathogenesis and Progression.ACS Infect Dis. 2024 Aug 9;10(8):2567-2583. doi: 10.1021/acsinfecdis.4c00385. Epub 2024 Jul 22. ACS Infect Dis. 2024. PMID: 39038212 Review.
-
Matrix metalloproteinases in tuberculosis.Eur Respir J. 2011 Aug;38(2):456-64. doi: 10.1183/09031936.00015411. Epub 2011 Jun 9. Eur Respir J. 2011. PMID: 21659415 Review.
-
Doxycycline and HIV infection suppress tuberculosis-induced matrix metalloproteinases.Am J Respir Crit Care Med. 2012 May 1;185(9):989-97. doi: 10.1164/rccm.201110-1769OC. Epub 2012 Feb 16. Am J Respir Crit Care Med. 2012. PMID: 22345579 Free PMC article.
-
Early Secretory Antigenic Target-6 Drives Matrix Metalloproteinase-10 Gene Expression and Secretion in Tuberculosis.Am J Respir Cell Mol Biol. 2017 Feb;56(2):223-232. doi: 10.1165/rcmb.2016-0162OC. Am J Respir Cell Mol Biol. 2017. PMID: 27654284 Free PMC article.
-
Tuberculosis, pulmonary cavitation, and matrix metalloproteinases.Am J Respir Crit Care Med. 2014 Jul 1;190(1):9-18. doi: 10.1164/rccm.201311-2106PP. Am J Respir Crit Care Med. 2014. PMID: 24713029 Free PMC article.
Cited by
-
ERK1/2-CEBPB Axis-Regulated hBD1 Enhances Anti-Tuberculosis Capacity in Alveolar Type II Epithelial Cells.Int J Mol Sci. 2024 Feb 18;25(4):2408. doi: 10.3390/ijms25042408. Int J Mol Sci. 2024. PMID: 38397085 Free PMC article.
-
Inhibition of invadopodia formation by diosgenin in tumor cells.Oncol Lett. 2020 Dec;20(6):283. doi: 10.3892/ol.2020.12148. Epub 2020 Sep 23. Oncol Lett. 2020. PMID: 33014161 Free PMC article. Review.
-
Effects of a Matrix Metalloproteinase Inhibitor-Eluting Stent on In-Stent Restenosis.Med Sci Monit. 2020 Mar 26;26:e922556. doi: 10.12659/MSM.922556. Med Sci Monit. 2020. PMID: 32214058 Free PMC article.
-
Host-directed therapies in pulmonary tuberculosis: Updates on anti-inflammatory drugs.Front Med (Lausanne). 2022 Sep 23;9:970408. doi: 10.3389/fmed.2022.970408. eCollection 2022. Front Med (Lausanne). 2022. PMID: 36213651 Free PMC article. Review.
-
The Association between Circulating microRNAs and the Risk of Active Disease Development from Latent Tuberculosis Infection: a Nested Case-Control Study.Microbiol Spectr. 2022 Jun 29;10(3):e0262521. doi: 10.1128/spectrum.02625-21. Epub 2022 Apr 18. Microbiol Spectr. 2022. PMID: 35435753 Free PMC article.
References
-
- Dye C, Williams BG. The population dynamics and control of tuberculosis. Science. 2010;328:856‐861. - PubMed
-
- Sanou A, Bañuls A‐L, Van Anh NT, Godreuil S. Mycobacterium tuberculosis: Ecology and evolution of a human bacterium. J Med Microbiol. 2015;64:1261‐1269. - PubMed
-
- Hmama Z, Pena‐Diaz S, Joseph S, et al. Immunoevasion and immunosuppression of the macrophage by Mycobacterium tuberculosis. Immunol Rev. 2015;264:220‐232. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- No. CARS-36/China Agriculture Research System
- Project No. 2013DFG32500/MoSTRCUK International Cooperation Project
- Project No. 2017YFD0500901/National Key Research and Development Program
- Project No. GDW20151100036, GDW20161100071/High-end Foreign Experts Recruitment Program
- Project No. 31572487, 31873005 /National Natural Science Foundation of China
LinkOut - more resources
Full Text Sources